Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother’s smoking habits

Giovanni Federico¹, Martina Gori¹, Emioli Randazzo¹ and Francesco Vierucci²

Abstract

Objectives: This study was conducted to assess whether formula-fed infants had increased skin advanced glycation end-products compared with breastfed ones. We also evaluated the effect of maternal smoke during pregnancy and lactation on infant skin advanced glycation end-products accumulation.

Methods: Advanced glycation end-product–linked skin autofluorescence was measured in 101 infants.

Results: In infants born from non-smoking mothers, advanced glycation end-products were higher in formula-fed subjects than in breastfed subjects (0.80 (0.65–0.90) vs 1.00 (0.85–1.05), p < 0.001). Advanced glycation end-products in breastfed infants from smoking mothers were higher than in those from non-smoking mothers (0.80 (0.65–0.90) vs 1.00 (0.90–1.17), p = 0.009).

Conclusion: Formula-fed infants had increased amounts of advanced glycation end-products compared with the breastfed ones, confirming that breast milk represents the best food for infants. Breastfed infants from mothers smoking during pregnancy and lactation had increased skin advanced glycation end-products, suggesting that smoke-related advanced glycation end-products transfer throughout breast milk. Moreover, advanced glycation end-products may already increase during gestation, possibly affecting fetal development. Thus, we reinforced that smoking must be stopped during pregnancy and lactation.

Keywords

Advanced glycation end-products, skin autofluorescence, infants, breast-feeding, smoke

Date received: 4 July 2016; accepted: 20 October 2016

Introduction

At present, a major problem in public health is the increasing incidence of age-related chronic diseases, such as obesity, diabetes, and cardiovascular and renal disorders. Even if clinical manifestations of these diseases are not apparent during pediatric age, pre-clinical alterations may be already present.¹² Recently, it has been reported that substances such as advanced glycation end-products (AGEs) are important contributors to oxidative stress and to inflammatory injury that promote and maintain vascular damage.³⁻⁵ AGEs are produced through non-enzymatic glycation of proteins, lipids, or nucleic acids within the so-called Maillard reaction. This process, occurring also under physiological conditions, is exacerbated by hyperglycemia, hyperlipidemia, or increased oxidative stress.⁶ AGEs may alter cellular functions via non-receptor-dependent and receptor-dependent mechanisms. For example, AGE-induced modification of the amino acids in the active center of an enzyme may alter its activity. In the receptor-dependent mechanism, AGEs bind to specific receptors inducing intracellular processes such as oxidative stress or inflammation.⁶

The Maillard reaction is important during food heating, giving them specific color and taste. It implies that in

¹Unit of Pediatric Endocrinology & Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
²Pediatric Unit, San Luca Hospital, Lucca, Italy

Corresponding author:
Giovanni Federico, Unit of Pediatric Endocrinology & Diabetes, University Hospital of Pisa, via Roma 67, 56126 Pisa, Italy.
Email: giovanni.federico@med.unipi.it
addition to diabetes mellitus, in which AGEs are formed by exposure of body proteins and lipids to high blood glucose, a major source today is nutrition with the highest content found in heat-treated food, especially lipid-rich and protein-rich food. Approximately 10% of ingested AGEs are absorbed, and about two-thirds of them are deposited in tissues, where they remain biologically active and exert their pathological effects, similar to their endogenous counterparts. Thus, oxidative stress increases endogenous AGEs formation that, together with supply and tissue deposition of diet-derived AGEs, further increase oxidative stress and amounts of AGEs in tissues contributing, in a vicious loop, to the development of vascular complications in patients with and without diabetes.

Until recently, determination of tissue AGEs was based on skin biopsy examination. In the last few years, a non-invasive optical method has given the opportunity to measure AGE-linked skin autofluorescence (sAF). This technique has proven to be well related to skin AGE accumulation and, being painless and easy-to-use, is particularly suitable for children. In addition, the availability of age-specific reference data makes the assessment of sAF easier. It should be underlined that plasma levels of AGEs do not reflect tissue accumulation and, in contrast to tissue AGEs, are not predictive for cardiovascular morbidity. In patients with type 2 diabetes mellitus, sAF was higher in those with macrovascular complications than in those with microvascular complications only or in patients without complications. In other studies, sAF demonstrated a predictive value, better than HbA1c and diabetes duration, to develop neuropathy and nephropathy. sAF was also associated with retinopathy and peripheral and autonomic neuropathy.

As regards cardiovascular risk, several studies demonstrated that sAF correlated with early vascular changes, such as vascular stiffness and intima-media thickness. In patients with peripheral artery disease, sAF was independently associated with all-cause mortality and fatal or non-fatal major adverse cardiovascular events within 5 years. Chronic kidney disease (CKD) is associated with increased amounts of AGEs so that patients with CKD stage 3, or terminal CKD, or persons undergoing dialysis displayed higher sAF. sAF was found to be a strong and independent predictor of CKD progression and was proposed to be used for the identification and monitoring of patients at risk of renal transplant dysfunction.

Since recently it was reported that formula milk contains higher amounts of AGEs in comparison with breast milk, in this study we measured sAF in a group of infants to assess whether formula-fed infants had increased content of AGEs in the skin in comparison with breastfed ones. As another external source of AGEs is represented by smoking, we also investigated the effect of smoking during pregnancy and breast-feeding on infant skin AGEs accumulation, in addition to birth weight and type of delivery.

**Methods**

**Study population**

We studied 131 healthy Caucasian infants (aged <4 months) who performed ultrasound screening of hip dysplasia at the Pediatric Unit of the University of Pisa during a 3-month period (April–June 2015). We chose this population to enroll healthy non-weaned subjects of similar age, to avoid confounding effects due to the intake of food other than milk. All infants were born at term (gestational age 37 weeks). Depending on feeding, we categorized them as breastfed or formula-fed infants. Mixed-fed infants were excluded (n = 8); none of the subjects were weaned. Other exclusion criteria were preterm delivery, Neonatal Intensive Care Unit hospitalization, and assumption of any drugs other than those administered for routine vitamin supplementation (n = 15).

A detailed oral interview was administered by one of us (F.V.) to infant’s mothers to provide general information about smoking (i.e. “Have you smoked cigarettes during pregnancy and lactation?”; “If yes, how many cigarettes/daily did you smoke?; “Are you still smoking?”). We identified as smoking mothers those smoking at least one cigarette daily during pregnancy and feeding (median = 6, range = 2–10). Non-smoking mothers were those who had never smoked during pregnancy and feeding. Infants born from women with different habits about smoking were excluded (n = 7). Skin pre-prandial morning AGEs were evaluated in 101 infants by measuring sAF (median gestational age = 40 weeks, range = 37–42 weeks; 31 born by caesarean delivery). We used the Italian reference growth charts to calculate birth weight SDS (standard deviation score) and birth length SDS.

**Assessment of skin sAF**

sAF was assessed using the AGE Reader device (Diagnoptics BV, Groningen, The Netherlands), as previously described. Briefly, the ratio of average light intensity per nanometer in the range between 420 and 600 nm emitted by the source divided by the average of excited light intensity per nanometer in the range between 300 and 420 nm was used as the measure of autofluorescence. The intra- and inter-day coefficient of variation was 2.6%. sAF was expressed as arbitrary units (AU) and was measured at three positions on the lateral side of the thigh, with the infant lying on the same side on a padded support, at the same level of the AGE Reader. In all infants, skin oils/ointments were not recently applied on the site of measurement before skin sAF assessment. The results of sAF were the mean of the three measurements.

**Statistical methods**

Continuous variables were checked for normal distribution by Kolmogorov–Smirnov test. Normally distributed variables were expressed as mean±standard deviation (SD),
while the non-normal distributed ones were reported as median and interquartile range (IQR).

As gestational age, birth weight SDS, and infant AGEs were not normally distributed, non parametric Mann–Whitney test was used to compare groups. Unpaired t-test was used to compare other continuous variables that were normally distributed. Fisher’s exact test or chi-square test was used to compare categorical variables, as appropriate.

AGE levels of infants born from non-smoking mothers were also expressed as mean±SD to give reference value, according to the type of feeding.

Table 1. Clinical details of the examined infants.

| Category         | N (%)          |
|------------------|----------------|
| Gender           |                |
| Males            | 52/101 (51.5)  |
| Females          | 49/101 (48.5)  |
| Type of delivery |                |
| Spontaneous      | 70/101 (69.3)  |
| Caesarean section| 31/101 (30.7)  |
| Type of feeding  |                |
| Breast-feeding   | 61/101 (60.4)  |
| Formula          | 40/101 (39.6)  |
| Mothers          |                |
| Non-smoking      | 86/101 (85.1)  |
| Smoking          | 15/101 (14.9)  |

| Category         | Mean (SD)          |
|------------------|--------------------|
| Birth length, SDS| 0.22 (0.95)        |
| Age at evaluation, days | 67.9 (19.6) |
| Weight at evaluation, kg | 5.27 (0.73) |
| Maternal age, years | 32.0 (5.1)       |

| Category         | Median (IQR)      |
|------------------|-------------------|
| Gestational age, weeks | 40 (39; 40)   |
| Birth weight, SDS  | −0.23 (−0.70; 0.62)|

SD: standard deviation; SDS: standard deviation score; IQR: interquartile range.

Spearman’s correlation coefficients were adopted to explore the relationship between infant AGE levels and continuous variables. Skin AGE results were logarithmically transformed to perform linear regression with age in both breastfed and formula-fed infants.

All statistical analyses were carried out using the SPSS (Statistical Package of Social Sciences, Chicago, IL, USA) software program version 20.0 for MAC OS. A p value < 0.05 was considered significant. Graphs in Figure 1 were performed using PRISM 6.00 for MAC OS (GraphPad Software, La Jolla, CA, USA).

Ethics statement and informed consent details

The study was approved by the Ethics Committee for Human Investigation at our Institution. Written informed consent to the study was obtained from all the parents of the enrolled children.

Results

Table 1 summarizes the clinical details of the examined population. The comparison between breastfed and formula-fed infants whose mothers were non-smoking (n = 86) is reported in Table 2. In particular, infants did not differ in post-natal age, weight, and gestational age. Interestingly, the amount of skin AGEs was statistically higher in formula-fed subjects than in breastfed subjects. However, infants did not differ in

![Figure 1. Linear regression analysis between logarithmically transformed skin AGEs and age, depending on the type of feeding: (a) entire sample (R² = 0.068, p = 0.015, Y = 0.00149*X - 0.171), (b) breastfed infants (R² = 0.083, p = 0.036, Y = 0.00164*X - 0.218), and (c) formula-fed infants (R² = 0.167, p = 0.18, Y = 0.00200*X - 0.144).](image-url)
Table 2. Comparison of auxological variables and skin AGE levels in breastfed and formula-fed infants born from non-smoking mothers.

|                              | Breastfed infants | Formula-fed infants | p    |
|------------------------------|-------------------|--------------------|------|
|                              | (n = 53)          | (n = 33)           |      |
| Birth length, SDS            | 0.27 (0.85)       | 0.44 (0.89)        | 0.381|
| Age at evaluation, days      | 69.4 (18.6)       | 64.2 (21.6)        | 0.243|
| Weight at evaluation, kg     | 5.27 (0.73)       | 4.87 (0.89)        | 0.026|
| Maternal age, years          | 31.6 (4.8)        | 33.6 (5.0)         | 0.067|
|                              | Median (IQR)      | Median (IQR)       | p    |
| Gestational age, weeks       | 40 (39; 40)       | 39 (39; 40)        | 0.268|
| Birth weight, SDS            | 0.01 (−0.61; 0.84)| −0.15 (−0.64; 0.55)| 0.517|
| Skin AGEs, AU                | 0.80 (0.65; 0.90) | 1.00 (0.85; 1.05)  | <0.001|

AGE: advanced glycation end-product; SD: standard deviation; SDS: standard deviation score; AU: arbitrary units; IQR: interquartile range.

Table 3. Comparison of auxological variables and skin AGE levels in breastfed infants and in formula-fed infants considering mother’s smoking habits.

|                              | Breastfed infants, non-smoking mothers (n = 53) | Breastfed infants, smoking mothers (n = 8) | p   | Formula-fed infants, non-smoking mothers (n = 33) | Formula-fed infants, smoking mothers (n = 7) | p   |
|------------------------------|-----------------------------------------------|-------------------------------------------|-----|--------------------------------------------------|---------------------------------------------|-----|
|                              | Mean (SD)                                     | Mean (SD)                                 |     | Mean (SD)                                        | Mean (SD)                                   |     |
| Birth length, SDS            | 0.27 (0.85)                                   | −0.49 (1.48)                              | 0.038| 0.44 (0.89)                                     | −0.34 (0.90)                                | 0.043|
| Age at evaluation, days      | 69.4 (18.6)                                   | 69.3 (20.1)                               | 0.986| 64.2 (21.6)                                     | 73.3 (17.7)                                | 0.307|
| Weight at evaluation, kg     | 5.27 (0.74)                                   | 4.48 (0.59)                               | 0.005| 4.87 (0.89)                                     | 4.92 (0.56)                                | 0.875|
| Maternal age, years          | 31.6 (4.8)                                    | 29.5 (6.2)                                | 0.278| 33.6 (5.0)                                     | 30.7 (4.8)                                 | 0.173|
|                              | Median (IQR)                                  | Median (IQR)                              | p   | Median (IQR)                                     | Median (IQR)                               | p   |
| Gestational age, weeks       | 40 (39; 40)                                   | 40 (39; 41)                               | 0.449| 39 (39; 40)                                     | 40 (38; 40)                                | 0.822|
| Birth weight, SDS            | 0.01 (−0.61; 0.84)                            | −0.57 (−1.13; −0.25)                      | 0.033| −0.15 (−0.64; 0.55)                            | −1.02 (−1.87; −0.9)                        | 0.004|
| AGEs, AU                     | 0.80 (0.65; 0.90)                             | 1.00 (0.90; 1.17)                         | 0.009| 1.00 (0.85; 1.05)                               | 1.00 (0.90; 1.10)                          | 0.784|

AGE: advanced glycation end-product; AU: arbitrary units; IQR: interquartile range; SD: standard deviation; SDS: standard deviation score.

development of AGEs when analyzed according to sex, birth weight, and type of feeding (data not shown).

AGE values (mean ± SD) for breastfed and formula-fed infants born from non-smoking mothers were 0.81 ± 0.20 and 0.99 ± 0.25, respectively.

We observed a direct, positive correlation between AGEs and days of life at evaluation either in the whole population (r = 0.276, p = 0.010) or after splitting in breastfed (r = 0.286, p = 0.038) and formula-fed (r = 0.422, p = 0.014) infants. Figure 1 shows the linear regression analysis between logarithmically transformed skin AGEs and age, depending on the type of feeding. The amount of AGEs did not relate to gestational age, birth weight SDS, birth length SDS, weight at evaluation, and maternal age (data not shown).

Table 3 summarizes the results according to both the type of feeding and the habit of mothers to smoke during pregnancy and feeding. Infants born from smoking mothers had a significantly reduced birth weight SDS and birth length SDS in comparison with those born from non-smoking mothers. Moreover, breastfed infants born from smoking mothers had reduced weight at evaluation in comparison to those born from non-smoking women.

Interestingly, among breastfed infants, the amount of AGEs found in ones from smoking mothers were significantly higher than in those from mothers who had never smoked. As regards formula-fed infants, skin AGEs amount was similar between infants from mothers who smoked during pregnancy and feeding and those from mothers who had never smoked.

**Discussion**

In our study, we assessed the accumulation of AGEs in the skin performed by using a completely non-invasive technique. Our data showed that formula-fed infants had higher amounts of skin AGEs than the breastfed counterparts. To our knowledge, we reported for the first time that infants...
whose mothers smoked during pregnancy and breast-feeding had increased deposition of AGEs in their skin in comparison with breastfed infants whose mothers had never smoked.

Data on behavior of AGEs in infants are scarce in the literature.\textsuperscript{19,43,47,48} Recently, proteomic characterization of AGEs in commercial milk samples\textsuperscript{42} demonstrated that submitting milk to heat treatment, to preserve microbiological safety and to prolong shelf life, induced important physicochemical changes in milk proteins, depending on the duration/extent of the heating procedure. Among these changes there is the production of AGEs. Since several studies suggested that food-derived AGEs may play a role in a wide range of harmful health effects, for example, diabetogenic, pro-oxidative, and pro-inflammatory events,\textsuperscript{3,5,15,49} one is wondering whether the intake of AGE-rich infant food, that is, formula milk, may precondition infants to metabolic and cardiovascular diseases. Our study was not designed to explore in depth this topic; consequently, our results cannot provide a clear answer. Nonetheless, we observed a significant, but limited, increase in skin AGE values (about 1 SD when sAF was expressed as mean ± SD) in formula-fed infants over breastfed counterparts (Table 2). A recent paper reported a similar increase in circulating AGEs in 3- to 6-month-old and 7- to 10-month-old formula-fed infants in comparison with breastfed ones, which did not contribute to insulin resistance associated with consumption of formula milk. The difference disappeared in the 11- to 14-month age group due to intake of solid food in addition to breast milk.\textsuperscript{40} The same authors also studied skin AGEs during a wide age range, spanning from few days to 77 years old population.\textsuperscript{47} They reported that in subjects ≤6 months old, values of skin AGEs were lower than we found in both breastfed and formula-fed individuals (sAF: 0.52 ± 0.16 and 0.67 ± 0.20, respectively). We do not have a clear explanation for that, but data from that study showed, in general, slightly lower sAF than that reported by Koetsier et al.\textsuperscript{19} in the Dutch population. Future studies reporting sAF normative data from different countries will contribute to clarify these observed differences among populations.

In our subjects, we observed a positive relationship between days of life and skin AGEs, irrespective of the type of feeding. This relationship, present during life,\textsuperscript{19,47} possibly reflects a progressive accumulation of AGEs in skin.

In regard to infants of smoking mothers, their skin AGEs were higher than those observed in breastfed infants from mothers who had never smoked, but not significantly different from formula-fed infants. In addition, we did not observe any additional effect of smoking habit on formula feeding. There was not, in fact, any significant difference between skin AGEs in formula-fed infants and in formula-fed infants from smoking mothers. However, these infants were born lighter and thinner and were smaller than infants from non-smoking mothers at the assessment of AGEs. It is well known that smoking during pregnancy represents a major cause of small for gestational age newborns. Mericq et al.\textsuperscript{50} showed a high significant correlation between maternal and infant circulating AGEs before the introduction of exogenous food to the infant. This correlation was observed in newborns and in breastfed infants, supporting a maternal transmission of AGEs throughout the placenta and breast milk. Thus, one could hypothesize that smoking-derived AGEs accumulate in both the mothers, contributing to affect placental development and function, and in the fetus, disturbing fetal development. In this case, in fact, excessive accumulation of AGEs starts very early in fetal life, exposing the fetus to an elevated oxidant stress state during a period of life so important for programming of fetal functions. Indeed, detrimental effects on health, although not evident in the immediate time frame, can become manifest later in life. To confirm our hypothesis, future studies should evaluate whether newborns of smoking mothers have higher post-partum sAF in comparison with ones born from non-smokers and whether human breast milk of smokers contains higher amounts of AGEs. In addition, the possible role of other lifestyle-related factors in changing the AGE content of human milk should be assessed.

Our cross-sectional study had some limitations. The enrolled sample is relative small, particularly regarding the number of smoking mothers. However, we expected this limitation considering that smoking in pregnancy and feeding is universally deprecated. Second, we did not evaluate maternal diet, with particular attention to consumption of AGE-rich foods. Finally, we did not consider a follow-up to determine whether the difference in skin AGEs between breastfed and formula-fed infants may persist with time.

**Conclusion**

Our data confirmed that formula-fed infants had increased amounts of skin AGEs in comparison with the breastfed counterparts. Even if this increase was limited and at present there is no clear evidence in the literature that it may be harmful to infant health, our results confirmed that breast milk represents undoubtedly the best food for infants. However, as formula milk becomes extremely important for newborns and infants from mothers who cannot breast-feed, industries producing formula milk should make any efforts to produce formulas with the possible lowest amount of AGEs.

Skin AGEs in breastfed infants from smoking mother were as high as those observed in formula-fed counterparts. However, as mothers were smoking during pregnancy, AGEs had already increased during fetal life, possibly affecting fetal development. After delivery, smoke-related AGEs transfer throughout breast milk may maintain amounts of AGEs higher than normal in the newborn/infant. Thus, the habit of smoking must be stopped during pregnancy and lactation, as worldwide recommended.\textsuperscript{51}

**Acknowledgements**

The authors thank Mrs. Caterina Di Donato, nurse, for her valuable assistance. G.F. and F.V. designed the study and drafted the manuscript.
M.G., E.R., and F.V. performed infant skin advanced glycation end-products evaluation. G.F. and F.V. performed statistical analysis. All authors contributed to interpretation of data, critically revised the manuscript, provided final approval, and agreed to be accountable for all aspects of work ensuring integrity and accuracy.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
This is an observational study performed using a quick, not invasive, quite painless, optical method (see Negrean et al.16 and Conway et al.26 to assess skin AGEs in babies who had undergone an ultrasound examination of their hips (a not invasive, painless method, as well). According to the Ethics Committee for Human Investigation of our Institution, we collected a written informed consent from babies’ parents who had undergone an ultrasound examination of their hips (a not invasive, painless method, as well). According to the Ethics Committee for Human Investigation of our Institution, we collected a written informed consent from babies’ parents.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Written informed consent was obtained from babies’ parents before the study.

Trial registration
An ethics approval number was not applicable to our study, according to the Ethics Committee for Human Investigation of our Institution.

References
1. Lamotte C, Iliescu C, Libersa C, et al. Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies. Eur J Pediatr 2011; 170(6): 719–729.
2. Palombo C, Kozakova M, Morizzo C, et al. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovase Diabetol 2011; 10: 88.
3. Ceriello A, Ilhat MA and Thorpe JE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009; 94(2): 410–415.
4. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001; 44(2): 129–146.
5. Vlassara H and Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 2004; 5(3): 181–188.
6. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005; 1043: 452–460.
7. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54(11): 3103–3111.
8. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48(4): 870–880.
9. Cai W, Gao QD, Zhu L, et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8(7): 337–346.
10. Goldberg T, Cai W, Peppa M, et al. Advanced glyccoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104(8): 1287–1291.
11. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94(12): 6474–6479.
12. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168(2): 213–220.
13. Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002; 163(2): 303–311.
14. Sandu O, Song K, Cai W, et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycoxitin intake. Diabetes 2005; 54(8): 2314–2319.
15. Uribarri J, Cai W, Sandu O, et al. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043: 461–466.
16. Negrean M, Stirban A, Strammann B, et al. Effects of low- and high-advanced glycation end-glycation products meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85(5): 1236–1243.
17. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47(7): 1324–1330.
18. Smit AJ and Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct depositions: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19(6): 527–533.
19. Koetsier M, Lutgers HL, de Jonge C, et al. Reference values of skin autofluorescence. Diabetes Technol Ther 2010; 12(5): 399–403.
20. Hartog JW, Hummel YM, Voors AA, et al. Skin autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008; 14(7): 596–602.
21. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29(12): 2654–2659.
22. Noordzij MJ, Mulder DJ, Oomen PH, et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus—a multi-centre study. Diabet Med 2012; 29(12): 1556–1561.
23. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. *Diabetes Care* 2008; 31(3): 517–521.

24. Chabroux S, Canouil-Poitirine F, Reffet S, et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. *Diabetes Metab* 2010; 36(2): 152–157.

25. Sugisawa E, Miura J, Iwamoto Y, et al. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. *Diabetes Care* 2013; 36(8): 2339–2345.

26. Conway BN, Aroda VR, Maynard JD, et al. Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. *Diabetes Care* 2011; 34(4): 1000–1005.

27. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. *Diabetologia* 2005; 48(8): 1637–1644.

28. Kitahara T, Ono K, Tsuchida A, et al. Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients. *Am J Kidney Dis* 2005; 46(4): 688–696.

29. Sims TJ, Rasmussen LM, Oxlund H, et al. The role of glycation cross-links in diabetic vascular stiffening. *Diabetologia* 1996; 39(8): 946–951.

30. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. *Metabolism* 2008; 57(10): 1452–1457.

31. Watfa G, Soulis G, Tartagni E, et al. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. *Diabetes Metab* 2012; 38(5): 413–419.

32. Lutgers HL, Graaff R, de Vries R, et al. Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease. *Eur J Clin Invest* 2010; 40(9): 812–817.

33. De Vos LC, Mulder DJ, Smit AJ, et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. *Arterioscler Thromb Vasc Biol* 2014; 34(4): 933–938.

34. Baynes JW and Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. *Free Radic Biol Med* 2000; 28(12): 1708–1716.

35. Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. *Kidney Int* 2000; 57(6): 2571–2585.

36. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glyco-toxins reduces excessive advanced glycation end products in renal failure patients. *J Am Soc Nephrol* 2003; 14(3): 728–731.

37. McIntyre NJ, Fluck RJ, McIntyre CW, et al. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. *Clin J Am Soc Nephrol* 2011; 6(10): 2356–2363.

38. McIntyre NJ, Chesterton LJ, John SG, et al. Tissue-advanced glycation end product concentration in dialysis patients. *Clin J Am Soc Nephrol* 2010; 5(1): 51–55.

39. Tanaka K, Nakayama M, Kanno M, et al. Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study. *PLoS One* 2013; 8(12): e83799.

40. Hartog JW, de Vries AP, Bakker SJ, et al. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. *Nephrol Dial Transplant* 2006; 21(8): 2263–2269.

41. Pischetsrieder M and Henle T. Glycation products in infant formulas: chemical, analytical and physiological aspects. *Amino Acids* 2012; 42(4): 1111–1118.

42. Renzone G, Arena S and Sculoni A. Proteomic characterization of intermediate and advanced glycation end-products in commercial milk samples. *J Proteomics* 2015; 117: 12–23.

43. Sebeková K, Saavedra G, Zumpe C, et al. Plasma concentration and urinary excretion of N epsilon-(carboxymethyl)lysine in breast milk- and formula-fed infants. *Ann N Y Acad Sci* 2008; 1126: 177–180.

44. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. *Proc Natl Acad Sci U S A* 1997; 94(25): 13915–13920.

45. Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. *J Pediatr Gastroenterol Nutr* 2010; 51(3): 353–361.

46. Meerwaldt R, Links T, Graaff R, et al. Simple noninvasive measurement of skin autofluorescence. *Ann N Y Acad Sci* 2005; 1043: 290–298.

47. Simon Klenovics K, Kolláróvá R, Hodosy J, et al. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. *Diabet Med* 2014; 31(5): 581–585.

48. Klenovics KS, Boor P, Somoza V, et al. Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption. *PLoS One* 2013; 8(1): e53056.

49. Sebeková K and Somoza V. Dietary advanced glycation end-products (AGEs) and their health effects—PRO. *Mol Nutr Food Res* 2007; 51(9): 1079–1084.

50. Méricq V, Piccardo C, Cai W, et al. Maternally transmitted food-derived glyco-toxins: a factor preconditioning the young to diabetes? *Diabetes Care* 2010; 33(10): 2232–2237.

51. WHO Guidelines Approved by the Guidelines Review Committee. *Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice*. 3rd ed. Geneva: World Health Organization, 2015.